Efficacy News and Research

RSS

RBD and NTD antibody cocktail could prevent the emergence of SARS-CoV-2 escape mutants

A new bioRxiv* preprint demonstrates how a combination of antibodies to two different regions on the viral spike could enhance neutralization efficiency as well as prevent the emergence of resistant variants.

15 Jun 2021

Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study

It has been uncertain whether antibodies produced via this non-canonical pathway are protective against SARS-CoV-2. In a new study, recently released as a preprint on the bioRxiv*server, the neutralization potency of these antibodies is compared with those traditionally produced in germinal center-based antiviral responses.

15 Jun 2021

Researchers screen dual main protease-cathepsin L inhibitors against SARS-CoV-2

In a recent study released on the bioRxiv* preprint server, a selective dual inhibitor of MPRO and cathepsin L is described, producing synergistic results that suppress SARS-CoV-2 infection.

15 Jun 2021

Alkaloids show potential as treatments for COVID-19

To further study these organic compounds, researchers from Kermanshah University of Medical Sciences, Iran, and Universidad de Santiago de Chile, Chile, reviewed the role of alkaloids as a potential antiviral, specifically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They presented the chemistry, plant sources, and antiviral effects of alkaloids and their anti-SARS-CoV-2 effect.

15 Jun 2021

Treatment-resistant depression relieved by laughing gas

Researchers at the Washington University School of Medicine in St. Louis and the University of Chicago have found that a single, one-hour treatment involving the inhalation of a mixture of oxygen and the anesthetic drug nitrous oxide, also known as laughing gas, can improve symptoms of depression in people resistant to treatment.

15 Jun 2021

SARS-CoV-2 variant of concern could cause further epidemics in UK

The team – from the University of Warwick, the University of Manchester, and the University of Oxford – say that a variant of concern that has either a substantial transmission advantage over resident lineages, or the ability to evade vaccine- or infection-induced immunity, can be expected to drive a wave of infections and hospitalizations similar to that seen in the country during the winter of 2020-21.

14 Jun 2021

Artificial intelligence for predicting TMB-H colorectal cancer from histopathological characteristics

Biomarkers are important determinants of appropriate and effective therapeutic approaches for various diseases including cancer.

14 Jun 2021

Cell therapy improves outcomes for heart failure patients, clinical trial shows

A clinical trial conducted at the University of Louisville has shown for the first time that heart failure treatments using cells derived from the patient's own bone marrow and heart resulted in improved quality of life and reduced major adverse cardiac events for patients after one year.

14 Jun 2021

Researchers examine the importance of time after COVID-19 vaccination

A new study has been published on the medRxiv* preprint server, which deals with the importance of time post-vaccination based on the quantification of VOC immune evasion. The current study developed a toy model to estimate the effectiveness of the vaccines against VOC over time. Researchers have shown that the estimated value is highly dependent on time post-vaccination. Additionally, this model can describe the implications of changes in vaccine efficacy against VOC.

14 Jun 2021

Robust immunity against SARS-CoV-2 with Pfizer vaccine is mediated by memory B cells

A reassuring study, released as a preprint on the medRxiv* server, from a multi-institutional team of researchers in Italy suggests that with the Pfizer-BioNTech BNT162b2 vaccine, post-vaccination immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is both robust and durable.

14 Jun 2021

Intranasal monoclonal SARS-CoV-2 antibody therapy shows promise in preclinical trials

A new study, released as a preprint on the bioRxiv* server, presents a new monoclonal antibody (MAb) called DZIF-10c that powerfully neutralizes SARS-CoV-2, including the current variants of concern (VOCs). With high bioavailability in the lungs and wide distribution in the body, the antibody was able to prevent SARS-CoV-2 infection in mice after intranasal administration.

14 Jun 2021

Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

Enterprise Therapeutics Ltd today announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis therapy, ETD001.

14 Jun 2021

Joint ICMRA and WHO statement explains how COVID-19 vaccines are regulated for safety, effectiveness

Healthcare professionals and public health authorities have a central role in discussing vaccination against COVID-19 with their patients.

13 Jun 2021

Role of traditional medicine against SARS-CoV-2

A group of researchers at Kannur University reviewed selected papers and in silico work on potential drug leads that could be used to manage COVID-19.

13 Jun 2021

Study reveals maternal and neonatal benefits of Pfizer COVID-19 mRNA vaccine

A new commentary, published as an ‘In-Press Preview’ in the Journal of Clinical Investigation, addresses the salient issue of vaccination against the coronavirus disease (COVID-19) in pregnancy and potential antibody transfer to the fetus – and provides the evidence in support of messenger RNA (mRNA) vaccine safety and efficacy for both maternal and child health.

13 Jun 2021

Study shows poor antibody response in naive elderly of nursing homes after mRNA vaccination

A new study describes inadequate antibody responses to the Pfizer/BioNTech vaccine against coronavirus disease 2019 (COVID-19) in elderly residents of a care home with no prior history of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compared to those with such a history. This adds to the current understanding of vaccine efficacy against infection.

13 Jun 2021

New radiopharmaceutical shows therapeutic efficacy in preclinical model of ovarian cancer

Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and decreasing tumor mass.

11 Jun 2021

High single-dose efficacy of Pfizer vaccine against SARS-CoV-2 in older adults

In British Columbia (BC), Canada, vaccination against coronavirus disease 2019 (COVID-19) began with the Pfizer/Moderna mRNA (messenger ribonucleic acid) vaccines began with nursing home residents and frontline healthcare workers. These are known to have a high protective efficacy of 92-93% after a single dose, but this data comes from younger and healthy adults, for the most part.

11 Jun 2021

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

A new study, released on the bioRxiv* preprint server, supports the efficacy of the wildtype ChAdOx1 nCoV-19 (AZD1222) vaccine against B.1.351, B.1.617.1 and B.1.617.2, while showing that a booster dose of vaccine based on the B.1.351 spike induces further increase in antibody titers.

11 Jun 2021

Scientists detect delayed and reduced antibody responses after BioNTech/Pfizer COVID-19 vaccination in older adults

Researchers at the U.S. Centers for Disease Control and Prevention (CDC) detected delayed and reduced antibody and T cell responses after immunization with BNT162b2 or the Pfizer-BioNTech COVID-19 vaccine in older adults compared with healthcare workers in Germany.

11 Jun 2021

Efficacy News and Research

RBD and NTD antibody cocktail could prevent the emergence of SARS-CoV-2 escape mutants

Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study

Researchers screen dual main protease-cathepsin L inhibitors against SARS-CoV-2

Alkaloids show potential as treatments for COVID-19

Treatment-resistant depression relieved by laughing gas

SARS-CoV-2 variant of concern could cause further epidemics in UK

Artificial intelligence for predicting TMB-H colorectal cancer from histopathological characteristics

Cell therapy improves outcomes for heart failure patients, clinical trial shows

Researchers examine the importance of time after COVID-19 vaccination

Robust immunity against SARS-CoV-2 with Pfizer vaccine is mediated by memory B cells

Intranasal monoclonal SARS-CoV-2 antibody therapy shows promise in preclinical trials

Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

Joint ICMRA and WHO statement explains how COVID-19 vaccines are regulated for safety, effectiveness

Role of traditional medicine against SARS-CoV-2

Study reveals maternal and neonatal benefits of Pfizer COVID-19 mRNA vaccine

Study shows poor antibody response in naive elderly of nursing homes after mRNA vaccination

New radiopharmaceutical shows therapeutic efficacy in preclinical model of ovarian cancer

High single-dose efficacy of Pfizer vaccine against SARS-CoV-2 in older adults

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

Scientists detect delayed and reduced antibody responses after BioNTech/Pfizer COVID-19 vaccination in older adults

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News